Eurofarma
Eurofarma, officially known as Eurofarma Laboratórios S.A., is a prominent Brazilian pharmaceutical company headquartered in São Paulo, Brazil. Established in 1972, Eurofarma has grown to become a key player in the Latin American pharmaceutical industry, with a strong presence across various operational regions, including Central and South America. Specialising in the development, manufacturing, and marketing of prescription medicines, generics, and over-the-counter products, Eurofarma is recognised for its commitment to quality and innovation. The company’s diverse portfolio includes therapeutic areas such as oncology, cardiology, and central nervous system disorders, setting it apart with its focus on patient-centric solutions. With a robust market position, Eurofarma has achieved significant milestones, including numerous certifications and awards for excellence in pharmaceutical practices, reinforcing its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Eurofarma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofarma's score of 60 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eurofarma's reported carbon emissions
In 2024, Eurofarma reported total carbon emissions of approximately 50,093,000 kg CO2e. This figure includes Scope 1 emissions of about 21,450,000 kg CO2e, Scope 2 emissions of around 4,340,000 kg CO2e, and Scope 3 emissions totalling approximately 24,303,000 kg CO2e. The previous year, 2023, saw total emissions of about 41,604,000 kg CO2e, with Scope 1 at approximately 16,992,000 kg CO2e, Scope 2 at about 7,827,000 kg CO2e, and Scope 3 at around 16,785,000 kg CO2e. Eurofarma has set ambitious climate commitments, aiming for the neutralisation of 100% of its direct CO2 emissions (Scope 1) by 2030, making it the first Brazilian pharmaceutical company to publicly commit to this goal. Additionally, the company plans to neutralise its Scope 2 emissions by 2038, with a projected reduction of 260,000 metric tons of CO2 through a new energy park in Bahia. These initiatives reflect Eurofarma's dedication to sustainability and its proactive approach to addressing climate change, positioning the company as a leader in the pharmaceutical industry in Brazil.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 12,594,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,611,000 | 0,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 6,146,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eurofarma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
